Testai L, Bianucci A M, Massarelli I, Breschi M C, Martinotti E, Calderone V
Dipartimento di Psichiatria, Neurobiologia, Farmacologia e Biotecnologie, Università degli Studi di Pisa, Via Bonanno, 6, I-56126 Pisa - Italy.
Curr Med Chem. 2004 Oct;11(20):2691-706. doi: 10.2174/0929867043364351.
Many non-cardiovascular drugs of common clinical use cause, as an unwanted accessory property, the prolongation of the cardiac repolarisation process, due to the block of the HERG (Human Ether-a-go-go Related Gene) potassium channel, responsible for the repolarising I(Kr) current. This delayed cardiac repolarisation process can be often unmasked by a prolongation of the QT interval of the ECG. In these conditions, premature action potentials can generate morphologically anomalous after-polarisations, and trigger a dangerous kind of polymorphic ventricular tachyarrhythmia, known as torsade de pointes, which can evolve in ventricular fibrillation and death. The risk associated with the torsadogenic cardiotoxicity of drugs, which prolong the QT interval has been the topic of documents produced by many health authorities, giving important issues about the preclinical and clinical evaluation of cardiac safety. Besides, public and private research laboratories developed several experimental in vitro or in vivo strategies, aimed to an early recognition of the influence of a drug (or of a drug-candidate) on the HERG channel and/or on the cardiac repolarisation process. Also the identification of a possible pharmacophore model, common in all or at least in numerous torsadogenic drugs, could represent a first step for the development of useful in silico approaches, allowing a preliminary indication about the potential torsadogenic property of a given molecule. In this work, we described the electrophysiological basis of torsade de pointes and listed several pharmacological classes of torsadogenic drugs. Among them, we focused our attention on antipsychotics, with an accurate overview on the experimental and clinical reports about their torsadogenic properties. Moreover, a common structural feature exhibited by these drugs, despite of their remarkable chemical differences, is evidenced by a computational approach and is indicated as a possible "facilitating" requirement for their torsadogenic properties. Together with other remarks, coming from different computational studies, the individuation of a satisfactory "toxicophore" model could be greatly useful, for the theoretical prediction of torsadogenic properties of a given chemical moiety and for the design of new drugs devoid of such an undesired and potentially lethal side-effect.
许多临床常用的非心血管药物会产生一种不良的附属特性,即由于阻断了负责复极化I(Kr)电流的人类醚 - 去极化相关基因(HERG)钾通道,导致心脏复极化过程延长。这种延迟的心脏复极化过程通常可通过心电图QT间期延长而显现出来。在这些情况下,过早的动作电位可产生形态异常的后除极,并引发一种危险的多形性室性心律失常,称为尖端扭转型室速,其可演变为心室颤动和死亡。与延长QT间期的药物致尖端扭转型室性心律失常心脏毒性相关的风险一直是许多卫生当局文件的主题,这些文件给出了关于心脏安全性临床前和临床评估的重要问题。此外,公共和私人研究实验室开发了几种体外或体内实验策略,旨在早期识别药物(或候选药物)对HERG通道和/或心脏复极化过程的影响。同样,识别所有或至少许多致尖端扭转型室速药物共有的可能药效团模型,可能代表了开发有用的计算机辅助方法的第一步,从而可以初步指示给定分子的潜在致尖端扭转型室速特性。在这项工作中,我们描述了尖端扭转型室速的电生理基础,并列出了几类致尖端扭转型室速药物。其中,我们将注意力集中在抗精神病药物上,准确概述了关于其致尖端扭转型室速特性的实验和临床报告。此外,尽管这些药物在化学结构上有显著差异,但通过计算方法证明了它们具有一个共同的结构特征,并表明这可能是其致尖端扭转型室速特性的一个“促进”条件。连同来自不同计算研究的其他评论,确定一个令人满意的“毒效团”模型对于理论预测给定化学部分的致尖端扭转型室速特性以及设计没有这种不良和潜在致命副作用的新药可能非常有用。